| | First author, publication year, country | Study characteristics | Population characteristics | Intervention and compairion | Follow-up time (M) | Outcomes | | Study design | Participants | Sample sizes (I/C) | Mean age (years, I/C) | Males (%, I/C) | Mean duration of DM (years, I/C) | Intervention group | Control group | Renal function | Lipid profile | Glycemic control | Blood pressure |
| | Khajehdehi 2011, Iran | Randomized, double-blind, placebo-controlled clinical trial | DKD | 20/20 | 52.9/52.6 | 45/65 | NA | Turmeric capsule 1500 mg/day, which included curcumin 66.3 mg/day | Placebo | 2 | SCr, PRO, BUN | TC, TG, HDL-C, LDL-C | FBG | SBP, DBP | | Jiménez-Osorio 2016, Mexico | Randomized, double-blind, placebo-controlled clinical trial | DKD | 28/23 | 73.9/67.9 | 55/56.2 | NA | Curcumin capsule 320 mg/day | Placebo | 2 | SCr, PRO | TC, TG | FBG | SBP, DBP | | Vanaie 2019, Iran | Randomized, double-blind, placebo-controlled clinical trial | DKD | 27/19 | 59/61 | 59/58 | 16/15 | Curcumin capsule 1500 mg/day | Placebo | 4 | SCr, BUN, PRO | TC, TG, HDL-C, LDL-C | FBG | NA | | Shafabakhsh 2020, Iran | Randomized, double-blind, placebo-controlled clinical trial | DKD | 26/27 | 58.3/56.2 | 65.4/55.6 | NA | Nanocurcumin capsule 80 mg/d | Placebo | 3 | SCr, BUN | TC, TG, HDL-C, LDL-C | FBG | SBP, DBP | | Martinez 2020, Mexico | Randomized, double-blind, placebo-controlled clinical trial | DKD | 54/46 | 59.3/57.4 | 57.4/78.3 | NA | Curcumin 1670 mg/day | Placebo | 6 | PRO | NA | NA | SBP, DBP |
|
|
SCr, serum creatinine; BUN, blood urea nitrogen; PRO, proteinuria; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; SBP; systolic blood pressure; DBP, diastolic blood pressure; DKD, diabetic kidney disease; FBG, fasting blood glucose; NA, not available; I, intervention group; C, control group; M, month.
|
